(Total Views: 532)
Posted On: 03/08/2021 11:30:01 PM
Post# of 149009
“The second part of that is Dr Kelly, as chairman along with the board needs to evaluate if the current CEO to see if a change is needed to get a much needed drug into the market for HIV and cancer.”
You’ll realize this is unlikely when you recognize that NP controls the SK and the BOD, not the other way around. The 2019 awards (soon to be returned) are a good example of that control. The failure of CD12 is squarely on NP’s shoulders yet the BOD sits quiet, with NP’s right hand man keeping them quiet. Wouldn’t you be quiet too if you were a BOD member getting hundreds of thousands of shares to simply vote in favor of what NP says?
You’ll realize this is unlikely when you recognize that NP controls the SK and the BOD, not the other way around. The 2019 awards (soon to be returned) are a good example of that control. The failure of CD12 is squarely on NP’s shoulders yet the BOD sits quiet, with NP’s right hand man keeping them quiet. Wouldn’t you be quiet too if you were a BOD member getting hundreds of thousands of shares to simply vote in favor of what NP says?
(5)
(0)Scroll down for more posts ▼
